Cantargia is focused on developing innovative antibody-based therapies that specifically target IL1RAP, a receptor implicated in various diseases. Their lead therapeutic candidate, nadunolimab (CAN04), is currently undergoing multiple clinical trials aimed at treating several types of cancer, including pancreatic cancer, triple-negative breast cancer, and non-small cell lung cancer. Additionally, Cantargia is advancing another antibody, CAN10, which is designed to address inflammatory and autoimmune diseases, with initial studies targeting conditions such as myocarditis and systemic sclerosis. The company is committed to exploring the efficacy of these therapies through rigorous clinical programs.

The scientific foundation of Cantargia's approach lies in the understanding of IL1RAP's role in disease mechanisms. By leveraging their expertise in antibody development, Cantargia aims to provide effective treatment options for patients suffering from both cancer and inflammatory disorders. Their ongoing clinical trials and research initiatives are designed to validate the therapeutic potential of their candidates, with a strong emphasis on generating robust clinical data to support their development programs.

Sweden

Cantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of solid tumors and hematoligacal cancers, entering phase I/IIa clinical development.

Cancer

Cardiovascular Diseases

Nervous System Diseases

Skin Diseases

Cantargia

Non-small cell lung carcinoma

Pancreatic ductal adenocarcinoma

Triple-negative breast cancer

Nadunolimab (CAN04)

Antibodies

Biologics

Acute Myocarditis

Systemic sclerosis

CAN10

Europe - West

Therapeutic

Cantargia

Company Details